Verona Pharma to Report Second Quarter 2022 Financial Results and Provide Corporate Update

Rhea-AI Summary

Verona Pharma (Nasdaq: VRNA) will announce its second-quarter financial results for the period ending June 30, 2022, on August 15, 2022. A conference call for investors is scheduled for 9:00 a.m. EDT to discuss these results and provide updates on the company’s operations. Verona Pharma is a clinical-stage biopharmaceutical company dedicated to developing therapies for respiratory diseases, specifically through its product candidate, ensifentrine, which is currently in Phase 3 trials for COPD maintenance treatment.

Positive

• Engaged in a critical Phase 3 trial for ensifentrine, which may become a pioneering treatment for COPD.
• Multiple formulations of ensifentrine are in the pipeline, enhancing its potential market reach.

Negative

• None.

LONDON and RALEIGH, N.C., July 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the second quarter ended June 30, 2022 on Monday, August 15, 2022 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.

To participate, please dial one of the following numbers and reference conference ID 5684286:

• +1-888-317-6003 for callers in the United States
• +1-412-317-6061 for international callers

A live webcast will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com, and the audio replay will be available for 90 days.

For further information please contact:

Verona Pharma plc	US Tel: +1-833-417-0262 UK Tel: +44 (0)203 283 4200
Victoria Stewart, Director of Investor Relations and Communications	info@veronapharma.com
Argot Partners (US Investor Enquiries)	Tel: +1-212-600-1902 verona@argotpartners.com
Kimberly Minarovich / Michael Barron
Optimum Strategic Communications (International Media and European Investor Enquiries)	Tel: +44 (0)203 882 9621 verona@optimumcomms.com
Mary Clark / Rebecca Noonan / Zoe Bolt

About Verona Pharma

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.

FAQ

When will Verona Pharma report its financial results for Q2 2022?

Verona Pharma will report its Q2 2022 financial results on August 15, 2022.

What is the focus of Verona Pharma's product candidate, ensifentrine?

Ensifentrine is being developed as a dual-action therapy for respiratory diseases, particularly COPD.

What are the upcoming events related to Verona Pharma's financial results?

Verona Pharma will host an investment community conference call on August 15, 2022, at 9:00 a.m. EDT.

What is the significance of the ENHANCE trial for Verona Pharma?

The ENHANCE trial is critical as it evaluates ensifentrine for COPD maintenance treatment, which could lead to regulatory approval.